Skip to main content
SpringerLink
Log in

Pharmacokinėtics of intravenous and oral cyclophosphamide in the presence of methotrexate and fluorouracil

  • Original Articles
  • Published:
Pharmaceutisch Weekblad Aims and scope Submit manuscript

Abstract

Cyclophosphamide was administered to 12 breast cancer patients in combination with methotrexate and fluorouracil. Doses prescribed were cyclophosphamide 75 mg/m2, methotrexate 30 mg/m2 and fluorouracil 500 mg/m2 (per square meter body surface). Cyclophosphamide was administered intravenously and orally in aqueous solutions and in tablets in a randomized cross-over trial. Methotrexate and fluorouracil were administered intravenously, methotrexate was given first and then fluorouracil. Assays of cyclophosphamide in blood plasma were performed by capillary gas chromatography. Data of mean bioavailability of cyclophosphamide administered by tablets were suggestive of sufficient absorption. In 2 patients, however, a lower bioavailability of cyclophosphamide was demonstrated. Intra-individual differences in the terminal slope of the plasma decay curves after intravenous and oral administration in some patients decreased the calculated bioavailability of cyclophosphamide, if these values were included in the calculation of cyclophosphamide bioavailability. Compared with the administration of the solutions peak times, lag-times and mean absorption times of cyclophosphamide given in tablets were markedly prolonged. It is concluded that interactions between cyclophosphamide and methotrexate and/or fluorouracil after oral dosing as tablets are different from interactions observed after intravenous administration of cyclophosphamide.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hill DL. A review of cyclophosphamide. Springfield: Charles C. Thomas, 1975:3–340.

    Google Scholar 

  2. Cox PJ, Farmer PB, Jarman M, eds. Symposium on the metabolism and mechanism of action of cyclophosphamide. Cancer Treat Rep 1976:299–525.

  3. Brock N, Hohorst H-J. The problem of specificity and selectivity of alkylating cytostatics: studies onN-2-chloroethylamido-oxaza-phosphorines. Z Krebsforsch Klin Onkol 1977:185–215.

  4. Friedman OM, Myles A, Colvin M. Cyclophosphamide and related phosphoramide mustards. Current status and future prospects. Adv Cancer Chemother 1979:143–204.

  5. Colvin M, Hilton J. Pharmacology of cyclophosphamide and metabolites. Cancer Treat Rep 1981;65(suppl 3):89–95.

    Google Scholar 

  6. Grochow LB, Colvin M. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 1980;380–94.

  7. D'Incalci M, Bolis G, Fachinetti T, et al. Decreased half life of cyclophosphamide in patients under continuous treatment. Eur J Cancer 1979;15:7–10.

    PubMed  Google Scholar 

  8. Juma FD, Robers HJ, Trounce JR. Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration. Br J Clin Pharmacol 1979;8:209–17.

    PubMed  Google Scholar 

  9. Slee PHThJ, De Bruijn EA, Driessen OMJ, Van Oosterom AT. Pharmacokinetics of the cytostatic drugs used in the CMF-regimen. Anticancer Res 1983;3: 269–72.

    PubMed  Google Scholar 

  10. Wagner Th, Fenneberg K. Pharmacokinetics and bioavailability of cyclophosphamide from oral formulations. Arzneimittelforsch/Drug Res 1984;34(1):313–6.

    Google Scholar 

  11. Wagner Th, Fenneberg K. Bioavailability of cyclophosphamide from oral formulations. Eur J Clin Pharmacol 1984;26:269–70.

    PubMed  Google Scholar 

  12. Matthias M, Sohr R, Preiss R, Brockmann B. Untersuchungen zur Bioverfuegbarkeit von Cyclophosphamid nach peroraler Applikation im hohen Dosisbereich. Onkologie 1984;7:48–9.

    PubMed  Google Scholar 

  13. Struck RF, Alberts DS, Horne K, Phillips JG, Peng Y-M, Roe DJ. Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, crossover trial. Cancer Res 1987;47:2723–6.

    PubMed  Google Scholar 

  14. Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981;304:10–5.

    PubMed  Google Scholar 

  15. De Bruijn EA, Van Oosterom AT, Tjaden UR. The influence of ethanol on cyclophosphamide pharmacokinetics and metabolism in tumor-bearing rats. Pharmacol Ther 1987;33:171–7.

    PubMed  Google Scholar 

  16. De Bruijn EA, Tjaden UR, Van Oosterom AT, Leeflang P, Leclerq PA. Determination of the underivatized antineoplastic drugs cyclophosphamide and 5-fluorouracil and some of their metabolites by capillary gas chromatography combined with electron-capture and nitrogen-phosphorus selective detection. J Chromatogr 1983;279:603–9.

    PubMed  Google Scholar 

  17. Van den Bosch N, De Vos D. Some aspects of gas-liquid chromatographic analysis of cyclophosphamide in plasma. J Chromatogr 1980;183:49–56.

    PubMed  Google Scholar 

  18. De Bruijn EA, Driessen O, Van den Bosch N, Van Strijen E. A gas-chromatographic assay for the determination of 5,6-dihydrofluorouracil and 5-fluorouracil in human plasma. J Chromatogr 1983;278:283–9.

    PubMed  Google Scholar 

  19. De Bruijn EA, Van Oosterom AT, Leclercq PA, De Haan JW, Van de Ven LJM, Tjaden UR. Monitoring the behaviour of 4-ketocyclophosphamide during capillary gas chromatography by mass spectrometry. Biom Mass Spectr 1987;14:643–7.

    Google Scholar 

  20. Jackson AJ, Chen M-L. Application of moment analysis in assessing rates of absorption for bioequivalency studies. J Pharm Sci 1987;1:6–9.

    Google Scholar 

  21. Jochemsen R, Nesselman JGJ, Hermans J, Van Boxtel CJ, Breimer DD. Pharmacokinetics of brotizolam in healthy subjects following intravenous and oral administration. Br J Clin Pharmacol 1983;16:285S-290S.

    PubMed  Google Scholar 

  22. Collier PS, Riegelman S. A new method for estimating absolute bioavailability from plasma level measurements of drugs. Abstracts of the 41th International Congress of Pharmaceutical Sciences of FIP, Vienna, 1981:174.

  23. De Bruijn EA, Driessen O, Leeflang PA, et al. Pharmacokinetic interactions of cyclophosphamide and 5-fluorouracil with methotrexate in an animal model. Cancer Treat Rep 1986;70:1159–65.

    PubMed  Google Scholar 

  24. De Bruijn EA, Driessen O, Leeflang P, Van Strijen E, Van den Bosch N, Hermans J. Interactions of methotrexate and cyclophosphamide with the pharmacokinetics of 5-fluorouracil in an animal model. Cancer Treat Rep 1987;71:1267–9.

    PubMed  Google Scholar 

  25. De Bruijn EA, Driessen O, Leeflang P, Van Strijen E, Van den Bosch N, Hermans J. Interactions of methotrexate and cyclophosphamide with cyclophosphamide pharmacokinetics. Submitted for publication.

  26. Van den Bosch N, Van Strijen E, Driesen O, De Bruijn EA. Non-linear pharmacokinetics of orally administered cyclophosphamide in rats and its possible influence on effects. Naunyn-Schmiedebergs Arch Pharm 1985;330:81.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Cancer Research & Clinical Oncology, University of Antwerp, B-2610, Wilrijk, Belgium

    E. A. De Bruijn & A. T. Van Oosterom

  2. St. Antonius Ziekenhuis, P.O. Box 2500, 3430, EM Nieuwegein, the Netherlands

    P. H. TH. J Slee

  3. Onze Lieve Vrouwe Gasthuis, 1e Oosterparkstraat 179, 1091, HA Amsterdam, the Netherlands

    D. W. Lameijer & K. J. Roozendaal

  4. Center for Bio-Pharmaceutical Sciences, P.O. Box 9502, 2300, RA Leiden, the Netherlands

    U. R. Tjaden

Authors
  1. E. A. De Bruijn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. H. TH. J Slee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. T. Van Oosterom
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. W. Lameijer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K. J. Roozendaal
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. U. R. Tjaden
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

De Bruijn, E.A., Slee, P.H.T.J., Van Oosterom, A.T. et al. Pharmacokinėtics of intravenous and oral cyclophosphamide in the presence of methotrexate and fluorouracil. Pharmaceutisch Weekblad Scientific Edition 10, 200–206 (1988). https://doi.org/10.1007/BF01956871

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01956871

Keywords

Search

Navigation